· 2 min read
Defibrotide Protects Rabbit Hearts From Low-Blood-Flow Injury in Lab Study
By Kristense at Havdis AI Science Team, approved by Andreas Lyhammer
· 2 min read
By Kristense at Havdis AI Science Team, approved by Andreas Lyhammer

Based on the PubMed abstract — the full text of this paper was not freely available.
Berti and colleagues, writing in Thrombosis Research in 1992, studied defibrotide, a polydeoxyribonucleotide (a chain of DNA building blocks) derived from mammalian lungs, in isolated rabbit hearts. This is laboratory pharmacology, not a human or skin study.
The researchers perfused rabbit hearts at a very low flow rate (0.2 ml/min) to mimic ischemia, the lack of blood supply to tissue, then restored flow to 20 ml/min. Low flow caused the heart muscle to contract abnormally and beat irregularly, and raised calcium levels in the heart tissue and in its mitochondria, the cell's energy-producing structures, measured using atomic absorption spectroscopy.
Defibrotide reduced this abnormal contracture, corrected the irregular rhythm, and limited the calcium buildup, performing similarly to two reference substances, prostacyclin and nifedipine. It also triggered release of prostaglandin-like compounds, and a drug called indomethacin that blocks prostaglandin production completely cancelled defibrotide's protective effects. The authors conclude the heart-protective action works mainly through prostaglandins E2 and I2, which seem to curb calcium overload in heart cells.
The study used isolated rabbit hearts only, so it cannot show whether these effects occur in intact animals, in humans, or in other tissues such as skin.
Our reflection
This 1992 study is a reminder that polydeoxyribonucleotides were investigated for cardiovascular pharmacology long before their later use in tissue repair and skin science. It illustrates the chemical versatility of this molecule class across very different biological systems. At Havdis, we see such early mechanistic work as part of the long scientific foundation that today's PDRN research, including work on skin and wound repair, continues to build upon.
Source
Berti F, Rossoni G, Galli G, Magni F, Mantovani M, Calvani AB et al. (1992). Thrombosis research.
Read the paper on PubMedDOI: 10.1016/0049-3848(92)90221-u
This article is written by Havdis's AI Science Team to explain published research. It is not medical advice, and nothing here is a claim about any Havdis product.
Related
A 1993 European Journal of Pharmacology study on how defibrotide, a polydeoxyribonucleotide, binds adenosine A1 and A2 receptors in lab experiments.
Read more →1992 Life Sciences study on how defibrotide, a PDRN sodium salt, may fight blood clots via free-radical scavenging and immune cell modulation.
Read more →1991 Angiology study: defibrotide limited calcium-driven neutrophil activation in lab tests, offering an early mechanistic clue for this PDRN-class drug.
Read more →